IOP elevation in glaucomatous eyes
| Time after OHT surgery | Treatment | N | Mean IOP (mmHg) ± SEM | Peak IOP (mmHg) | |||
|---|---|---|---|---|---|---|---|
| Glaucoma | Control | Difference | Glaucoma | Control | |||
| 3 weeks | Vehicle | 15 | 36 ± 0.6 | 24 ± 0.2 | 12 ± 0.6 | 39 ± 0.6 | 26 ± 1.2 |
| XPro1595 | 15 | 37 ± 0.7 | 25 ± 0.2 | 12 ± 0.6 | 41 ± 1.7 | 26 ± 0.6 | |
| GIKY 52466 | 7 | 35 ± 0.8 | 24 ± 0.5 | 11 ± 0.7 | 39 ± 1.4 | 26 ± 0.5 | |
| PhTx 343 | 5 | 35 ± 1.0 | 24 ± 0.6 | 11 ± 1.4 | 39 ± 1.3 | 26 ± 0.6 | |
IOP elevation in glaucomatous eyes treated with different compounds. Mean and peak IOP elevations for each cohort of rats exposed to 3 weeks of ocular hypertension (OHT) after treatment with XPro1595, GIKY 52466, PhTX 343, or vehicle (n = 5–15/group).